Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback

Impact · against what's priced in

The court ruling validates the worst-case legal outcome for LQDA, which the previous price explicitly declined to pay for, triggering a massive correction. For UTHR, the impact is positive but the specific degree to which this victory was priced in is unknown.

LQDA−0.90: Challenges what's priced in
The price assumes: The worst-case scenario from the '327 trial, which implies up to a 58% loss if injunctive relief or heavy royalties are imposed.
The price previously declined to pay for the worst-case '327 trial outcome; the ruling that two claims are valid and infringed by Yutrepia realizes this risk, resulting in a 57% price plunge.
What LQDA's price assumes · Sep 13

Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback

biotech
healthcare
pharmaceuticals
LQDA
UTHR
court ruling
fda
litigation
patent dispute

Search tags

Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback

What matters in this story

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback

What matters in this story

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

How each ticker is affected

Connected tickers

Track these names every morning.

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

UNICYCIVE DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. - BBNX

Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback

What matters in this story

Next reads from the same story arc

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback

What matters in this story

Next reads from the same story arc

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

How each ticker is affected

Connected tickers

Track these names every morning.

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

UNICYCIVE DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. - BBNX